ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (State o ...

ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of $6.43 for proceeds to the company of $5,306,000. The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the wo ...

Nutriband Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real- time, interactive presentation on the Emerging Growth Conference All sessions will be conducted through video webcasts and will take place in the Eastern time zone. ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq: NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growt ...

Core Viewpoint - Nutriband Inc. CEO Gareth Sheridan will temporarily step aside to participate in the Irish Presidential Election, with Chairman Serguei Melnik taking over as interim CEO during this period [1][2][3] Company Leadership Transition - Gareth Sheridan will step down for three months, with the nomination hearings and election occurring in September and October [1] - Serguei Melnik, co-founder and Chairman, will assume CEO responsibilities and guide the company towards its NDA filing target in 2026 [2] Strategic Focus - Melnik, with over 20 years of experience in capital markets, will continue to execute the company's strategic development and focus on enhancing shareholder value [2] - Sheridan emphasized the strength of the company's team as its core asset and expressed confidence in meeting planned targets during his absence [3] Product Development - Nutriband's lead product, AVERSA Fentanyl, has received FDA approval for a meeting request, positioning it as a potential first-of-its-kind abuse-deterrent opioid patch [4] - AVERSA Fentanyl is projected to achieve peak annual US sales between $80 million and $200 million, with plans to expand into major global markets [4] Intellectual Property - The AVERSA technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including the US, Europe, and China [5] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with AVERSA technology designed to prevent the abuse and accidental exposure of drugs with abuse potential [6]

FDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry, Manufacturing, and Controls plans for the product through commercialization. Nutriband is partnering with Kindeva to develop AVERSA™ FENTANYL which combines Nutriband’s AVERSA™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. ORLANDO, Fla., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription tr ...

Company Overview - Nutriband Inc. is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4] - The AVERSA™ technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, particularly fentanyl [3][4] Preferred Stock Dividend - Nutriband is issuing a 25% preferred stock dividend, where shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held [1] - The pay date for the new issuance is set for August 5, 2025 [1] Conversion and Dividend Details - Each preferred share will be convertible into one share of common stock upon FDA approval of the AVERSA Fentanyl product [2] - If not converted, preferred shares will receive an annual cash dividend from the company's profits, as determined by the Board of Directors [2]

Core Points - Nutriband Inc. has declared a 25% preferred stock dividend, with shareholders of record on July 25, 2025, receiving one preferred share for every four common shares held, payable on August 5, 2025 [1] - Each preferred share will be convertible to one common share following FDA approval of the AVERSA Fentanyl product, and if unconverted, will receive annual cash dividends from company profits as determined by the Board of Directors [2] - The CEO emphasized the company's focus on creating shareholder value and advancing the commercialization of the AVERSA Fentanyl product, highlighting recent progress in manufacturing scale-up with Kindeva [3] Product Information - AVERSA™ technology is designed to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly fentanyl, while ensuring accessibility for patients in need [4] - Nutriband is primarily focused on developing transdermal pharmaceutical products, with the AVERSA™ abuse-deterrent fentanyl patch as its lead product [5] Company Overview - Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products, with a strong emphasis on abuse-deterrent technologies [5]

Company Overview - Nutriband Inc. has been added to multiple Russell indexes, including the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 reconstitution [1][2] - The company focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [6] Product and Technology - AVERSA™ technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly fentanyl [5] - The potential peak annual US sales for AVERSA Fentanyl are estimated to be between $80 million and $200 million [2] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] - FTSE Russell, the global index provider, emphasizes the importance of adapting indexes to reflect the evolving US economy, with a transition to semi-annual reconstitution planned for 2026 [4]

Core Viewpoint - Nutriband has successfully completed the commercial manufacturing process scale-up for its lead product, Aversa™ Fentanyl, in partnership with Kindeva, marking a significant milestone towards developing a commercially viable abuse-deterrent fentanyl patch [1][3]. Group 1: Product Development - Aversa™ Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, and is manufactured at Kindeva's advanced transdermal facility in the United States [2]. - The next steps include manufacturing clinical supplies and filing an Investigational New Drug (IND) application with the FDA to initiate a human abuse liability clinical study [2]. Group 2: Market Potential - Aversa Fentanyl has the potential to be the first abuse-deterrent opioid patch on the market, aimed at deterring abuse and reducing accidental exposure risks, with projected peak annual US sales between $80 million to $200 million [5]. - The company plans to initially focus on the US market while also targeting global markets due to the widespread unmet medical need for effective pain management [5]. Group 3: Technology and Intellectual Property - Nutriband's AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent drug abuse, ensuring that these medications remain accessible to patients in need [4][7]. - The technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including major markets such as the United States, Europe, and China [6][7].